The report reiterates BUY on Sai Life Sciences with a revised TP of INR 2,050, citing 29% YoY EBITDA growth, capacity expansion plans, and strong sales growth visibility of 25% CAGR over FY26-29E.
Read this note →Sai Life Sciences Limited
NSE SAILIFE BSE 544306 INE570L01029
0 filings · 0 analysed
1,837.00
+1.57%
over today
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities | 07 Nov 2026, 06:48 | long | 1,785.10 | 2,050.00 | — | — | open by 2027-11-07 |
| HDFC Securities | 07 Oct 2026, 15:25 | long | 1,561.80 | 1,580.00 | 1,542.30 | -100% | hit |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report expects 11% YoY revenue growth with soft CMC business but strong CRO growth, with margin expansion expected.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief